Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Current Deferred Revenue (2016 - 2019)

Ultragenyx Pharmaceutical (RARE) has disclosed Current Deferred Revenue for 4 consecutive years, with $69000.0 as the latest value for Q1 2019.

  • On a quarterly basis, Current Deferred Revenue fell 90.46% to $69000.0 in Q1 2019 year-over-year; TTM through Mar 2019 was $69000.0, a 90.46% decrease, with the full-year FY2017 number at $6.0 million, up 1655.43% from a year prior.
  • Current Deferred Revenue was $69000.0 for Q1 2019 at Ultragenyx Pharmaceutical, down from $1.2 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $6.0 million in Q4 2017 to a low of $69000.0 in Q1 2019.
  • A 4-year average of $1.0 million and a median of $637000.0 in 2017 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: soared 1655.43% in 2017, then crashed 90.46% in 2019.
  • Ultragenyx Pharmaceutical's Current Deferred Revenue stood at $341000.0 in 2016, then skyrocketed by 1655.43% to $6.0 million in 2017, then crashed by 79.22% to $1.2 million in 2018, then crashed by 94.45% to $69000.0 in 2019.
  • Per Business Quant, the three most recent readings for RARE's Current Deferred Revenue are $69000.0 (Q1 2019), $1.2 million (Q2 2018), and $723000.0 (Q1 2018).